George Fromm

Company: Shattuck Labs

Job title: Chief Scientific Officer

Seminars:

Dual CD47 Blockade & CD40 Immune Activation in Patients Treated With SL-172154 (SIRPα-Fc-CD40L), Results in M1 Macrophage Polarization & Evidence of Adaptive Immune Activation, Including Increased CD8 & GZMB in the TME 8:30 am

SL-172154, a hexameric bi-functional fusion protein consisting of SIRPα linked to CD40L via an inert Fc domain, was designed to simultaneously block CD47 and provide immune co-stimulation to CD40+ immune cells SL-172154 was tolerable as a monotherapy in patients with heavily pretreated platinum resistant ovarian cancers, and subsequently expanded into combination studies with liposomal doxorubicin…Read more

day: Day One